RyCarma Therapeutics

RyCarma Therapeutics is pioneering first-in-class therapeutics targeting ryanodine receptors (RyRs), a fundamental pathway in calcium signaling implicated in serious muscle diseases. Built on decades of foundational research from founder Dr. Andrew Marks, the company's platform has produced Rycals®, small molecules designed to repair dysfunctional RyRs and modify disease progression. The company is advancing its lead candidate, Surlorian, for heart failure and has programs for RYR1-related myopathies, leveraging prior Phase 2 clinical experience with an earlier Rycal molecule. With a seasoned leadership team and an exclusive license from Columbia University, RyCarma is positioned to address high-unmet-need conditions where current treatments are largely symptomatic.

Platform of small molecule therapeutics called Rycals® that target and stabilize dysfunctional ryanodine receptors (RyRs) to correct intracellular calcium signaling.

In heart failure, RyCarma faces competition from numerous large pharma and biotech companies developing both symptomatic and novel mechanistic therapies. In RYR1-RM, the competitive landscape is less crowded but includes other companies exploring gene therapy and small molecule approaches targeting muscle function and calcium handling.